

## STUDY SCHEMA

### Advanced Solid Tumor Cancers

- *HER2* amplification on MSK-IMPACT (fold change  $\geq 2$ ) or another NGS platform at CLIA laboratory, or ISH (*HER2/CEP17* ratio  $\geq 2.0$ ), or
- Lung cancer with *HER2* mutation (Cohort 1 only)

***HER2* MUTANT**

***HER2* AMPLIFIED**

**Cohort 1:  
Lung cancers**

**Cohort 2:  
Lung cancers**

**Cohort 3:  
Bladder and urinary tract cancers**

**Cohort 4:  
Other solid tumors**

Ado-trastuzumab emtansine at 3.6mg/kg IV every 3 weeks  
until disease progression by RECIST v1.1, modified PERCIST, or unacceptable toxicity

**Supplementary Figure 2. Consort diagram.** The diagram shows TDM-1 clinical trial study scheme